Skip to main content

Table 1 Baseline characteristics of patients in the CAD vs NCAD groups, and the stenosis vs non-stenosis subgroups

From: Association between omentin-1 expression in human epicardial adipose tissue and coronary atherosclerosis

 

CAD

NCAD (12)

Stenosis (15)

Non-Stenosis (13)

Total (28)

Clinical characteristics

 Age (years)

61.73 ± 4.28

60.08 ± 3.80

60.96 ± 4.08

58.50 ± 5.27

 Male (%)

8 (53.3)

10 (76.9)

18 (64.3)

5 (47.1)

 BMI (kg/m2)

25.48 ± 3.91

25.93 ± 2.82

25.69 ± 3.39

23.09 ± 2.32*§

 Waist circumference (cm)

90.11 ± 9.68

94.15 ± 13.31

91.99 ± 11.47

81.05 ± 8.94*§

 Hypertension (%)

4 (26.7)

3 (23.1)

7 (25.0)

1 (8.3)

 T2DM (%)

8 (53.3)

8 (61.5)

16 (57.1)

3 (25.0)

 Smoking (%)

9 (60.0)

9 (69.2)

18 (64.3)

4 (33.3)

 LVEF (%)

57.73 ± 10.31

55.92 ± 9.51

56.89 ± 9.80

56.58 ± 7.50

Laboratory examinations

 Fasting glucose (mmol/L)

5.35 (4.98, 7.30)

5.37 (5.02, 5.65)

5.36 (5.00, 6.30)

5.28 (4.77, 6.04)

 Glycosylated serum protein (%)

15.00 (14.20, 16.80)

14.50 (13.80, 17.20)

14.65 (13.88, 17.03)

14.55 (14.05, 17.75)

 Fasting insulin(μU/ml)

73.10 (13.40, 104.50)

9.80 (6.05, 47.70)

16.35 (7.98, 80.88)

22.30 (11.03, 26.20)

 HOMA-IR

2.49 (1.57, 6.71)

17.38 (3.82, 27.92)

4.28 (2.07, 25.75)

4.27 (2.40, 8.09)§

 Triglycerides (mmol/L)

1.32 (0.91, 2.04)

1.71 (1.15, 2.50)

1.52 (1.02, 2.22)

1.46 (1.07, 2.59)

 Total cholesterol (mmol/L)

4.25 ± 1.27

4.36 ± 0.88

4.30 ± 1.09

4.87 ± 1.32

 HDL-C (mmol/L)

0.96 (0.82, 1.18)

0.81 (0.73, 1.06)

0.88 (0.77, 1.17)

1.18 (0.89, 1.73)

 LDL-C (mmol/L)

2.74 ± 1.31

2.67 ± 0.93

2.70 ± 1.13

3.34 ± 0.84

 Serum creatinine (μmol/L)

74.60 (65.50, 83.10)

82.10 (76.15, 93.95)#

78.70 (66.98, 86.60)

79.90 (65.03, 84.13)

 Homocysteine (μmol/L)

15.50 (11.00, 21.90)

14.20 (11.40, 22.90)

14.35 (11.05, 21.90)

14.45 (10.93, 20.08)

 hsCRP (mg/L)

1.02 (0.38, 3.85)

1.01 (0.74, 2.28)

1.02 (0.57, 3.00)

2.35 (0.67, 5.09)

 BNP (pg/ml)

89.00 (43.00, 164.00)

85.00 (30.50, 169.50)

87.00 (43.00, 157.75)

165.5 (87.75, 252.25)

 cTnI (μg/L)

0.01 (0, 0.02)

0.01 (0, 0.015)

0.01 (0, 0.02)

–

Medications

 Aspirin (%)

6 (40.0)

8 (61.5)

14 (50.0)

0 (0)*§

 Nitrates (%)

13 (86.7)

13 (100)

26 (92.9)

2 (16.7)*§

 ACEI/ARB (%)

2 (13.3)

2 (15.4)

4 (14.3)

1 (8.3)

 Statins (%)

9 (60.0)

6 (46.2)

15 (53.6)

0 (0)*§

 β-blockers (%)

9 (60.0)

11 (84.6)

20 (71.4)

0 (0)*§

 Calcium channel blockers (%)

3 (20.0)

4 (30.8)

7 (25.0)

0 (0)

 Insulin (%)

2 (13.3)

2 (15.4)

4 (14.3)

1 (8.3)

 Oral hypoglycemic agents (%)

3 (20.0)

2 (15.4)

5 (17.9)

1 (8.3)

  1. Data are shown as mean ± SD, median (lower quartile, upper quartile), or number (%)
  2. CAD coronary artery disease, NCAD non-coronary artery disease, BMI body mass index, LVEF left ventricular ejection fraction, HOMA-IR homeostasis model assessment of insulin resistance, HDL-C high-density lipoprotein cholesterol, LDL-C low-density lipoprotein cholesterol, hsCRP high-sensitivity C-reactive protein, BNP brain natriuretic peptide, cTnI cardiac troponin I, T2DM type 2 diabetes, ACEI/ARB angiotensin-converting enzyme inhibitor/angiotensin II type 1 receptor blocker
  3. * P < 0.05, CAD group vs NCAD group
  4. § P < 0.05, non-stenosis subgroup vs NCAD group
  5. # P < 0.05, stenosis subgroup vs non-stenosis subgroup
Back to article page

Cardiovascular Diabetology

ISSN: 1475-2840